Strategies to enhance CAR-T persistence
Abstract Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute lymphoblastic leukemia (B-ALL), although the primary response rate is promising, the high incidence of early relapse h...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-11-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-022-00434-9 |
| _version_ | 1811186936747917312 |
|---|---|
| author | Yue Liu Lingna An Ruihao Huang Jingkang Xiong Haoyu Yang Xiaoqi Wang Xi Zhang |
| author_facet | Yue Liu Lingna An Ruihao Huang Jingkang Xiong Haoyu Yang Xiaoqi Wang Xi Zhang |
| author_sort | Yue Liu |
| collection | DOAJ |
| description | Abstract Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute lymphoblastic leukemia (B-ALL), although the primary response rate is promising, the high incidence of early relapse has caused modest long-term survival with CAR-T cell alone. One of the main challenges is the limited persistence of CAR-T cells. To further optimize the clinical effects of CAR-T cells, many studies have focused on modifying the CAR structure and regulating CAR-T cell differentiation. In this review, we focus on CAR-T cell persistence and summarize the latest progress and strategies adopted during the in vitro culture stage to optimize CAR-T immunotherapy by improving long-term persistence. Such strategies include choosing a suitable cell source, improving culture conditions, combining CAR-T cells with conventional drugs, and applying genetic manipulations, all of which may improve the survival of patients with hematologic malignancies by reducing the probability of recurrence after CAR-T cell infusion and provide clues for solid tumor CAR-T cell therapy development. |
| first_indexed | 2024-04-11T13:53:30Z |
| format | Article |
| id | doaj.art-2e8caa1940794659ba827c5b8e7a2f90 |
| institution | Directory Open Access Journal |
| issn | 2050-7771 |
| language | English |
| last_indexed | 2024-04-11T13:53:30Z |
| publishDate | 2022-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj.art-2e8caa1940794659ba827c5b8e7a2f902022-12-22T04:20:25ZengBMCBiomarker Research2050-77712022-11-0110111810.1186/s40364-022-00434-9Strategies to enhance CAR-T persistenceYue Liu0Lingna An1Ruihao Huang2Jingkang Xiong3Haoyu Yang4Xiaoqi Wang5Xi Zhang6Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical UniversityMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical UniversityMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical UniversityMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical UniversityMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical UniversityMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical UniversityMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical UniversityAbstract Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute lymphoblastic leukemia (B-ALL), although the primary response rate is promising, the high incidence of early relapse has caused modest long-term survival with CAR-T cell alone. One of the main challenges is the limited persistence of CAR-T cells. To further optimize the clinical effects of CAR-T cells, many studies have focused on modifying the CAR structure and regulating CAR-T cell differentiation. In this review, we focus on CAR-T cell persistence and summarize the latest progress and strategies adopted during the in vitro culture stage to optimize CAR-T immunotherapy by improving long-term persistence. Such strategies include choosing a suitable cell source, improving culture conditions, combining CAR-T cells with conventional drugs, and applying genetic manipulations, all of which may improve the survival of patients with hematologic malignancies by reducing the probability of recurrence after CAR-T cell infusion and provide clues for solid tumor CAR-T cell therapy development.https://doi.org/10.1186/s40364-022-00434-9ImmunotherapyCAR-T optimizationPersistenceDifferentiationMetabolism |
| spellingShingle | Yue Liu Lingna An Ruihao Huang Jingkang Xiong Haoyu Yang Xiaoqi Wang Xi Zhang Strategies to enhance CAR-T persistence Biomarker Research Immunotherapy CAR-T optimization Persistence Differentiation Metabolism |
| title | Strategies to enhance CAR-T persistence |
| title_full | Strategies to enhance CAR-T persistence |
| title_fullStr | Strategies to enhance CAR-T persistence |
| title_full_unstemmed | Strategies to enhance CAR-T persistence |
| title_short | Strategies to enhance CAR-T persistence |
| title_sort | strategies to enhance car t persistence |
| topic | Immunotherapy CAR-T optimization Persistence Differentiation Metabolism |
| url | https://doi.org/10.1186/s40364-022-00434-9 |
| work_keys_str_mv | AT yueliu strategiestoenhancecartpersistence AT lingnaan strategiestoenhancecartpersistence AT ruihaohuang strategiestoenhancecartpersistence AT jingkangxiong strategiestoenhancecartpersistence AT haoyuyang strategiestoenhancecartpersistence AT xiaoqiwang strategiestoenhancecartpersistence AT xizhang strategiestoenhancecartpersistence |